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Abstract
Summary: The serotonin-2 receptor antagonist ketanserin has been suggested 
to diminish arteriosclerotic development by its effect on platelet function and on 
vascular smooth muscle cells. We investigated the ability of ketanserin in reducing 
immune-mediated arteriosclerosis using the BN-WAG and WAG-BN rat aortic 
transplantation models. Ketanserin (10 mg/kg/day) administered in drinking water 
significantly reduced posttransplant arteriosclerotic thickening of the intima in the 
BN-WAG rat model to 102 ± 23 µm as compared with 171 ± 60 µm in untreated BN-
WAG allografts 8 weeks posttransplantation (p < 0.05). In the opposite WAG-BN 
combination, at 4 weeks posttransplantation, no significant reduction in intimal 
thickening was attained (112 ± 42 vs. 152 ± 49 µm). Platelet aggregation to 
increasing amounts of collagen did not show a correlation between the effect of 
ketanserin on platelet function and reduction in intimal thickening. Ketanserin had 
no effect on systolic blood pressure or mononuclear cell infiltration. We conclude 
that ketanserin reduces graft arteriosclerosis by a mechanism other than by 
inhibition of platelet function, decrease in blood pressure, or immunosuppression. 
Because of this antiarteriosclerotic effect, ketanserin therapy might be beneficial 
to the long-term survival of vascular allografts.
With decreasing numbers of acute graft loss, chronic rejection has become the 
major complication of clinical transplantation. In heart grafts, chronic rejection is 
dominated by concentric intimal thickening of the epicardial as well as the 
intramyocardial branches of the coronary arteries. Because of this localization 
pattern, this phenomenon is also termed graft vascular disease (GVD). The 
prevalence of GVD ranges from 2 to 18% at 1 year and from 50 to 73% at 5 years 
after transplantation (1-4). This narrowing of the coronary arteries is the major 
limiting factor in medium- and long-term graft survival after heart transplantation. 
That GVD is a major problem even during the first year after transplantation, 
resulting in 33 and 68% of patient death, has been reported by centers with long 
experience in heart transplantation (5,6). There is no current treatment for 
chronic rejection, and in patients with extensive GVD retransplantation remains 
the only option to prevent death (7).
The pathogenesis of graft arteriosclerosis has not yet been elucidated, but 
immunologic phenomena linked to histoincompatibility differences between donor 
and recipient is generally believed to result in the development of proliferative 
lesions (8,9). Repetitive endothelial injury with consequent platelet activation may 
thus contribute to the development of GVD (10,11).
Studies of the mechanism of classic atherosclerosis have generated a 
resurgence of interest in serotonin. Serotonin is stored in the dense granules of 
platelets and, when released, theoretically may stimulate thickening of the blood 
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vessel wall in several ways, first in the positive feedback that it exerts on platelet 
aggregation. By amplifying the release of other aggregatory stimuli, serotonin will 
facilitate ongoing platelet aggregation and thus the release of growth factors, in 
particular platelet-derived growth factor (PDGF) (12,13). Second, serotonin has 
been demonstrated to stimulate directly the mitogenesis of aortic vascular smooth 
muscle cells (VSMC) in culture. Although substantially less potent in this respect 
than PDGF, serotonin in low concentrations significantly potentiates the VSMC 
mitogenesis of PDGF (14). Last, serotonin may stimulate arteriosclerosis by its 
conceptive role in chronic hypertension (15). Indeed, blocking the serotonin-2 
(5-HT2) receptors by ketanserin, clinically applied as an antihypertensive agent, 
effectively antagonizes these effects of serotonin (16-18). Therefore, ketanserin 
has been suggested to provide protection to arteriosclerotic diseases (19).
In previous immunohistologic studies of graft arteriosclerosis in aortic 
allografts, we observed pre-dominantly actin-positive VSMC in late intimal lesions. 
Furthermore, we observed more severe arteriosclerotic alterations in the WAG-
Brown Norway (BN) rat strain combination than in the reverse combination (20). 
Because of our results showing that the BN has a stronger blood-clotting tendency 
than the WAG rat, in the present study we examined the role of platelet 
aggregation in the development of posttransplant arteriosclerotic lesions. We also 
tested the hypothesis that ketanserin provides vascular protection by affecting 
platelet function and by blocking directly the growth stimulation of VSMC by 
serotonin. The effects of ketanserin on blood pressure and on collagen induced 
platelet aggregation were monitored.
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METHODS
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Experimental animals
Male inbred BN (RT1n) and WAG (RT1u) rats were used. All animals were 
obtained from Harlan CPB, Austerlitz, The Netherlands, and had free access to 
food and water. Rats of both strains, weighing 200-250 g and aged 10-12 weeks, 
were used as recipient and donor. The experimental protocols were approved by 
the Committee on Animal Research of Erasmus University, Rotterdam and adhered 
to the Guidelines on the Protection of Experimental Animals of the Council of the 
EC (1986).
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Aorta transplantation
All rats were anesthetized with ether and underwent laparotomy. In the donor 
as well as the recipient, a segment of infrarenal aorta, [almost equal to]1 cm long, 
was isolated, excised, perfused with saline, and used as a transplant. Donor aorta 
was transplanted into orthotopic position. End-to-end anastomosis was performed 
with a 9.0 monofilament nylon suture (Eticon, Sommerville, NJ, U.S.A.). The 
ischemic time was 20-30 min.
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Ketanserin treatment
Ketanserin (Ketanserin-tartrate, Janssen, Beerse, Belgium) was given orally in 
a daily dose of 10 mg/kg, dissolved in drinking water. Although this dose of 
ketanserin is high as compared with human standards, no toxic side effects were 
noted in a pilot study. Ketanserin was dissolved in drinking water to maintain 
constant blood level. To prevent precipitation, a freshly prepared ketanserin 
solution was provided daily. We ascertained intake of 10 mg/kg ketanserin by each 
animal by measuring their daily water consumption.
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Experimental design
In a previous study, we observed an increase in intimal thickness in the BN-
WAG and WAG-BN aortic transplantation models as well as in BN and WAG aortic 
autotransplants (20). In the WAG-BN model, the process of intimal thickening was 
so rapid that severe lesions had already developed 4 weeks posttransplantation. 
Due to intense intimal thickening, thrombosis and necrosis, all allografts of this 
strain combination removed at later timepoints were not useful for evaluation. In 
the reverse combination (from the BN-WAG), intimal lesions developed more 
slowly. In this rat combination, a steady increase to severe lesions at 8 weeks was 
evident. Therefore, in this study, animals in the WAG-BN combination were killed 
at 4 weeks and those in the BN-WAG combination were killed at 8 weeks. The 
experiment was performed with four groups of rats. The different groups with 
corresponding treatments and numbers of the animals are shown in Table 1.
Table 1 
Page 2 of 7Ovid: Ketanserin Reduces Graft Arteriosclerosis After Allogeneic Aorta Transplantation i...
05-06-2015http://ovidsp.tx.ovid.com/sp-3.15.1b/ovidweb.cgi?QS2=434f4e1a73d37e8ce55b227ffaae...
Back to Top
Histology
Straight 5-µm cross-sections from tissues embedded in paraffin were prepared 
at three levels of the midportion of the graft and stained with hematoxylin-eosin 
and with elastic of Gieson. Slides were then examined by light microscopy. The 
thickness was measured with a calibrated ocular micrometer to evaluate the 
following variables: the intimal and medial thickness, adventitial infiltration, and 
SMC necrosis.
The average medial and thicknesses and maximal intimal thickness were 
determined. Cellularity of the adventitia, as a measure of cellular infiltration, and 
of the media, was assessed by counting the number of nuclei at five sites. The 
mean score was multiplied to a field of 0.1 mm2.
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In vitro platelet aggregation assays
Platelet function was measured at the times the animals were killed: at 4 
weeks posttransplantation in the WAG-BN model and at 8 weeks in the BN-WAG 
model. Blood from all animals receiving ketanserin and blood from 6 untreated 
transplanted BN and WAG rats each, as controls, were analyzed. In addition, 
platelet function of 3 BN and 3 WAG rats was tested 3 h after administration of a 
high dose of ketanserin by gastric intubation (50 mg/kg) to determine whether the 
dose of 10 mg/kg reduced platelet aggregation in the experimental animals. Under 
ether anesthesia, the animals received 50 IU heparin intravenously, after which 
the abdomen was opened. At the time of death, the abdominal aorta was dissected 
at its bifurcation, and blood was collected by aortic puncture. Platelets were 
aggregated with the Chronolog-Whole Blood Aggrometer (Chronolog U.K.). Collagen 
was chosen to induce platelet aggregation because of its likely physiological role in 
mediating platelet aggregation in vascular allografts. Increasing concentrations of 
0.025-2.50 mg/ml collagen were added to heparinized (10 U/ml) whole blood 
samples, which were diluted 1:1 with 0.9% saline. Ten-minute recordings of the 
induced changes in electrical resistance (impedance, in [OMEGA]) were analyzed 
by an Olivetti M24 PC. The amount of platelets was counted on a TOA platelet 
counter PL100.
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Measurement of blood pressure
The effect of ketanserin on systolic blood pressure was measured in conscious 
rats by the tail-cuff method with an electrosphygmomanometer (Narco Bio-
Systems, Houston, TX, U.S.A.). Measurements were made in both BN-WAG and 
WAG-BN transplanted rats receiving ketanserin as well as in the untreated 
transplanted control rats 1 week before and 0.5, 1, and 2 weeks after 
transplantation.
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Statistical analyses
The results are mean and SD. The data were assessed statistically by analysis 
of variance (ANOVA) followed by a Bonferroni t test; p < 0.05 was considered 
statistically significant.
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RESULTS
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Effect of ketanserin on graft arteriosclerosis
As shown in Table 1, ketanserin significantly reduced intimal thickening in the 
BN-WAG combination to 102 ± 23 µm as compared with 171 ± 60 µm in the 
allogeneic controls 8 weeks after transplantation (p < 0.05). In the WAG-BN 
combination, no significant inhibition was observed 4 weeks after transplantation 
(121 ± 64 vs. 152 ± 49 µm). Ketanserin treatment did not affect adventitial cellular 
infiltration or SMC necrosis. No toxic side effects of ketanserin were noted during 
the experimental period.
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Platelet aggregation
There was no difference in the number of platelets between the BN and WAG 
rat strains. Changes in electrical resistance as a result of collagen-induced platelet 
aggregation in the different experimental groups are shown in Figs. 1-3. Untreated 
BN platelets were more sensitive to collagen than WAG platelets. Collagen in a 
concentration as low as 0.050 mg/ml was effective in inducing BN platelet 
aggregation. A concentration of 0.200 mg/ml decreased electrical resistance by 
1.57 [OMEGA], whereas untreated WAG platelets were not affected at this 
Fig. 1 Fig. 2 Fig. 3 
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concentration. Aggregation of WAG platelets was observed only at collagen 
concentrations >=0.250 mg/ml. After ketanserin treatment, BN platelet 
aggregation was observed at collagen concentrations >=200 mg/ml, showing an 
aggregation pattern similar to that of untreated WAG platelets. WAG platelet 
function at low collagen concentrations was not altered by ketanserin treatment. 
At high concentrations of collagen, no difference in electric resistance was 
observed in either rat strains as compared with the untreated transplanted 
controls. Similar patterns of collagen-induced platelet aggregation were noted 3 h 
after high-dose ketanserin (50 mg/kg) administration to normal rats of the two 
different strains (Fig. 3). This finding supports a maximal therapeutic effect of 10 
mg/kg ketanserin as administered to the experimental animals.
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Effect of ketanserin on systolic blood pressure
Before transplantation, BN rats had systolic blood pressure of 125 ± 6 mm Hg 
as compared with 114 ± 7 mm Hg in untransplanted WAG rats. After BN-WAG and 
WAG-BN aortic transplantation, systolic blood pressure did not change in untreated 
controls (115 ± 7 and 121 ± 7 mm Hg at day 7 and 117 ± 8 and 126 ± 9 mm Hg at 
day 14 posttransplantation, respectively) or after ketanserin treatment (114 ± 7 
and 128 ± 9 mm Hg at day 7 and 116 ± 9 and 132 ± 8 mm Hg at day 14).
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DISCUSSION
Ketanserin has been suggested to provide vascular protection by blocking the 
effects of serotonin on platelets and SMC (19). Indeed, in the present study, the 
development of posttransplant arteriosclerosis was significantly reduced in the BN-
WAG combination. The ability of ketanserin to block 5-HT2 receptors therefore 
suggests that platelet-derived serotonin might be involved in the mechanism 
leading to posttransplant arteriosclerosis. Serotonin-mediated platelet aggregation 
has been demonstrated to be reduced by ketanserin (16,17). In the present study, 
the sensitivity of BN platelets was also reduced to low concentrations of collagen 
after ketanserin treatment. The inhibiting effect of ketanserin on BN platelet 
aggregation did not coincide with significant inhibition of the arteriosclerotic 
response in the WAG-BN aorta transplantation model, however. Similarly, in 
isografts, a greater sensitivity of BN platelets did not result in more pronounced 
arteriosclerotic lesions in BN rats than in WAG rats (20). On the other hand, intimal 
thickening was significantly reduced in the BN-WAG model, in which no effect of 
ketanserin on collagen-induced platelet aggregation could be detected. Therefore, 
we noted no correlation between the effect of ketanserin on platelet function and 
reduction of intimal thickening, which suggests that ketanserin might reduce 
arteriosclerosis by a mechanism other than by affecting platelet function.
A direct blocking effect by ketanserin on the serotonin-induced mitogenesis of 
VSMC is a likely explanation for the antiproliferative effect. In vitro, serotonin has 
been reported to stimulate the mitogenesis of aortic VSMC (14). Any 
immunosuppressive effect of ketanserin is unlikely because no differences in 
mononuclear cell infiltration were evident between ketanserin-treated and 
untreated allografts in the present study.
The significant reduction in intimal proliferation induced by ketanserin in the 
BN-WAG aortic model suggests that the stimulating effects of platelet-derived 
serotonin on the mitogenesis of VSMC might be of relatively greater importance in 
the BN-WAG model than in the WAG-BN model, possibly owing to differences in 
mononuclear cell infiltration in the two rat strain combinations (20). More severe 
cellular rejection in the WAG-BN combination may indicate a minor role of 
serotonin in the overall arteriosclerotic stimulation after aorta transplantation. On 
the contrary, relatively weaker rejection in the BN-WAG combination may provide 
local conditions that cause serotonin to be of significant importance in stimulating 
VSMC proliferation.
Ketanserin did not affect blood pressure during the experiment. This finding is 
in agreement with results of previous studies that showed a minor and brief 
response of blood pressure to ketanserin in conscious normotensive animals as 
compared with anesthetized animals or conscious hypertensive rats (21,22). The 
hypotensive effect of ketanserin therefore can be excluded as a mechanism 
leading to decreased graft arteriosclerosis.
Serotonin has been suggested to be a mediator of cyclic flow alterations in 
stenosed coronary arteries in dog studies. These flow variations are believed to be 
produced by platelet aggregation at the stenotic site alternating with thrombus 
dislodgement and embolization. The frequency and severity of cyclic flow 
alterations and platelet aggregation predict the severity of neointimal 
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proliferation. Ketanserin treatment was successful in abolishing these blood flow 
variations and in retarding neointimal proliferation (23,24). Our study showed a 
decrease in BN platelet sensitivity to low concentrations of collagen with no effect 
on maximal platelet aggregation. Therefore, an increase in the threshold of 
platelet activation by ketanserin treatment might explain the mechanism of 
alternating cyclic flow variations (24). This hypothesis is also in accord with the 
reported effect of ketanserin in prolonging rat tail bleeding time (25).
Used clinically, ketanserin causes a greater decrease in blood pressure in 
hypertensive or older patients (21,22,26). Similarly, ketanserin causes a 
considerably greater reduction in serotonin-induced platelet aggregation in older 
than in younger patients (27). These findings suggest that ketanserin might be 
more effective in reducing posttransplant arteriosclerosis when serotonin is of 
greater importance in the associated hemodynamic processes. A similar 
explanation was offered in a large clinical study of restenosis after coronary 
angioplasty in which no protective effect by ketanserin was detected. The lack of 
effect in this trial may indicate a minor role of serotonin in the complex biology of 
late restenosis (28). Future studies of ketanserin in older, hypertensive, or 
partially immunosuppressed animals may demonstrate its effects in reducing 
posttransplant arteriosclerosis.
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